Trial Profile
A Phase 1 Study of LY2523355 in Patients with Acute Leukemia.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 15 May 2019
Price :
$35
*
At a glance
- Drugs Litronesib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 01 Aug 2012 Actual end date Feb 2011 added as reported by ClinicalTrials.gov.
- 19 Nov 2011 Additional lead trial investigator identified as reported by M.D. Anderson Cancer Center record.
- 19 Nov 2011 New source identified and integrated (M.D. Anderson Cancer Center: 2009-0785).